MA40934A - Procédé de préparation de conjugués agent de liaison cellulaire-agent cytotoxique - Google Patents
Procédé de préparation de conjugués agent de liaison cellulaire-agent cytotoxiqueInfo
- Publication number
- MA40934A MA40934A MA040934A MA40934A MA40934A MA 40934 A MA40934 A MA 40934A MA 040934 A MA040934 A MA 040934A MA 40934 A MA40934 A MA 40934A MA 40934 A MA40934 A MA 40934A
- Authority
- MA
- Morocco
- Prior art keywords
- agent
- cytotoxic
- cytotoxic agent
- binding
- cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
La présente invention fournit un nouveau procédé de préparation d'un conjugué d'agent cytotoxique de liaison de cellules. Le procédé comprend les étapes consistant à: (a) faire réagir un agent cytotoxique avec un réactif de réticulation bifonctionnel représenté par la formule développée (i) ou un sel de celui-ci, dans une solution tampon comprenant un agent tampon pour fournir un premier mélange comprenant un agent cytotoxique- composé de liaison, dans lequel la solution tampon a une capacité tampon élevée; et (b) faire réagir le premier mélange comprenant l'agent cytotoxique-agent de liaison de l'étape (a) avec un agent de liaison cellulaire dans une solution ayant un ph de 4 à 9 pour fournir un deuxième mélange comprenant le conjugué agent cytotoxique . Les conjugués d'agents cytotoxiques de l'agent liant cellulaire préparés selon les procédés décrits ici sont également inclus dans la présente invention.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462081914P | 2014-11-19 | 2014-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40934A true MA40934A (fr) | 2017-09-27 |
Family
ID=54754814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040934A MA40934A (fr) | 2014-11-19 | 2015-11-18 | Procédé de préparation de conjugués agent de liaison cellulaire-agent cytotoxique |
Country Status (12)
Country | Link |
---|---|
US (2) | US10413615B2 (fr) |
EP (1) | EP3220959A1 (fr) |
JP (1) | JP2018505128A (fr) |
KR (1) | KR20170088905A (fr) |
CN (1) | CN107592813A (fr) |
AU (1) | AU2015349985A1 (fr) |
CA (1) | CA2966932A1 (fr) |
IL (1) | IL251900B (fr) |
MA (1) | MA40934A (fr) |
RU (1) | RU2711930C2 (fr) |
SG (1) | SG11201703599VA (fr) |
WO (1) | WO2016081584A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112022000297A2 (pt) | 2019-07-10 | 2022-03-15 | Cybrexa 3 Inc | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos |
CN114341162A (zh) | 2019-07-10 | 2022-04-12 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (fr) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotique C-15003 PHO et sa préparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
WO1982001188A1 (fr) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | Composes 4,5-deoxymaytansinoide et leur procede de preparation |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
SE9102074D0 (sv) | 1991-07-03 | 1991-07-03 | Kabi Pharmacia Ab | Tomour antigen specific antibody |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
CA2076465C (fr) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Conjugues agents de liaison cellulaire d'analogues et de derives de cc-1065 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
IL111748A0 (en) | 1993-12-03 | 1995-01-24 | Zeneca Ltd | Proteins |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5958872A (en) | 1996-04-01 | 1999-09-28 | Apoptosis Technology, Inc. | Active survival domains of IGF-IR and methods of use |
CA2297070A1 (fr) | 1997-08-01 | 1999-02-11 | Morphosys Ag | Nouvelle methode et nouveau phage d'identification d'une sequence d'acide nucleique |
TW593241B (en) | 1999-04-20 | 2004-06-21 | Hoffmann La Roche | Carbamic acid derivatives |
WO2001058479A1 (fr) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Utilisation du recepteur de l'interleukine 13, sous-unite alpha 2, dans l'immunotherapie |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
US6596503B1 (en) | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
HUP0302525A2 (hu) | 2001-01-05 | 2003-10-28 | Abgenix, Inc. | Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok |
US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
AU2003285878B2 (en) | 2002-11-07 | 2011-04-28 | Immunogen, Inc. | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
AU2004259398A1 (en) | 2003-06-27 | 2005-02-03 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
US20060045877A1 (en) | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
EP1817341A2 (fr) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Anticorps et immunoconjugues mis au point |
EA013323B1 (ru) | 2004-12-09 | 2010-04-30 | Сентокор, Инк. | Иммуноконъюгаты против интегрина, способы и варианты применения |
CA2600929A1 (fr) | 2005-03-04 | 2006-09-14 | Biogen Idec Ma Inc. | Methodes d'humanisation de regions variables d'immunoglobuline par modification rationnelle de residus determinant une complementarite |
MX2007014148A (es) * | 2005-05-19 | 2008-01-11 | Amgen Inc | Composiciones y metodos para incrementar la estabilidad de anticuerpos. |
EP1914242A1 (fr) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Nouveau anticorps Anti-CD38 pour le traitement du cancer |
AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
KR102444399B1 (ko) * | 2009-06-03 | 2022-09-16 | 이뮤노젠 아이엔씨 | 메이탄시노이드의 제조방법 |
AR078471A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS |
AR078470A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | Anticuerpos que se unen especificamente al receptor epha2 |
SG10201501342UA (en) | 2010-02-24 | 2015-04-29 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
MX338932B (es) | 2010-03-12 | 2016-05-06 | Immunogen Inc | Moleculas de union cd37 y sus inmunoconjugados. |
WO2012019024A2 (fr) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Molécules se liant à her3 et leurs immunoconjugués |
US9260483B2 (en) | 2011-01-10 | 2016-02-16 | Technische Universität München | Triazacyclononane-based phosphinate ligand and its use for molecular imaging |
RU2748733C2 (ru) * | 2011-02-15 | 2021-05-31 | Иммуноджен, Инк. | Цитотоксические производные бензодиазепина |
WO2012138749A1 (fr) * | 2011-04-04 | 2012-10-11 | Immunogen, Inc. | Procédés de réduction de la toxicité oculaire de conjugués anticorps-médicament |
EP2961434A2 (fr) * | 2013-02-28 | 2016-01-06 | ImmunoGen, Inc. | Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
EP3411077A1 (fr) * | 2016-02-05 | 2018-12-12 | ImmunoGen, Inc. | Procédé efficace de préparation de conjugués agent de liaison cellulaire-agent cytotoxique |
CN111587125A (zh) * | 2018-01-12 | 2020-08-25 | 伊缪诺金公司 | 抗体药物缀合、纯化和调配的方法 |
-
2015
- 2015-11-18 CA CA2966932A patent/CA2966932A1/fr not_active Abandoned
- 2015-11-18 RU RU2017115812A patent/RU2711930C2/ru active
- 2015-11-18 EP EP15802310.1A patent/EP3220959A1/fr not_active Withdrawn
- 2015-11-18 KR KR1020177016749A patent/KR20170088905A/ko unknown
- 2015-11-18 WO PCT/US2015/061310 patent/WO2016081584A1/fr active Application Filing
- 2015-11-18 JP JP2017525940A patent/JP2018505128A/ja not_active Ceased
- 2015-11-18 AU AU2015349985A patent/AU2015349985A1/en not_active Abandoned
- 2015-11-18 MA MA040934A patent/MA40934A/fr unknown
- 2015-11-18 SG SG11201703599VA patent/SG11201703599VA/en unknown
- 2015-11-18 US US15/527,525 patent/US10413615B2/en not_active Expired - Fee Related
- 2015-11-18 CN CN201580060700.2A patent/CN107592813A/zh active Pending
-
2017
- 2017-04-25 IL IL251900A patent/IL251900B/en not_active IP Right Cessation
-
2019
- 2019-08-07 US US16/534,521 patent/US20200101168A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SG11201703599VA (en) | 2017-06-29 |
WO2016081584A1 (fr) | 2016-05-26 |
JP2018505128A (ja) | 2018-02-22 |
KR20170088905A (ko) | 2017-08-02 |
RU2017115812A3 (fr) | 2019-06-18 |
US10413615B2 (en) | 2019-09-17 |
US20200101168A1 (en) | 2020-04-02 |
CA2966932A1 (fr) | 2016-05-26 |
RU2017115812A (ru) | 2018-12-19 |
RU2711930C2 (ru) | 2020-01-23 |
IL251900B (en) | 2019-12-31 |
IL251900A0 (en) | 2017-07-31 |
EP3220959A1 (fr) | 2017-09-27 |
AU2015349985A1 (en) | 2017-05-25 |
US20170354742A1 (en) | 2017-12-14 |
CN107592813A (zh) | 2018-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021001311A (es) | Compuestos de 1h-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (tlr7) y metodos y usos para los mismos. | |
NZ629204A (en) | Anti-vla1 (cd49a) antibody pharmaceutical compositions | |
PE20190177A1 (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco | |
BR112021025034A2 (pt) | Imunoconjugado, composto aminobenzazepina-ligante, composição farmacêutica, métodos para tratar câncer e para preparar um imunoconjugado e uso de um imunoconjugado | |
MA41134B1 (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
CR20200590A (es) | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas | |
EP3778917A3 (fr) | Anticorps multispécifiques, analogues d'anticorps, compositions et procédés | |
MX2021010674A (es) | Compuestos triciclicos condensados utiles como agentes anticancerigenos. | |
MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
MX351975B (es) | Composiciones y metodos para el tratamiento de infecciones y tumores. | |
WO2012147107A3 (fr) | Nouveaux procédés améliorés destinés à la préparation de dérivés d'indoline et composition pharmaceutique associée | |
MX2022005404A (es) | Compuestos de fijación a il-2r e il-7r dual. | |
JO3811B1 (ar) | مركبات غير متجانسة حلقياً ثلاثية الحلقات ملتحمة تعمل في صورة مثبطات انزيم إنتيجراز hiv | |
WO2012177837A3 (fr) | Nouveaux dérivés de maytansinoïde comprenant un lieur peptidique et conjugués correspondants | |
MX2022010515A (es) | Conjugacion mediada por transglutaminasa. | |
MA38315B1 (fr) | Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales | |
EA201071178A1 (ru) | Усовершенствованные способы гашения нежелательных побочных реакций при патогенной инактивации эритроцитов | |
MA34308B1 (fr) | Triazolopyridines substituées | |
JP2014526250A5 (fr) | ||
GEP20094680B (en) | Piperazinylpiperidine derivatives as chemokine receptor antagonists | |
WO2008003155A3 (fr) | Procédés de préparation de penta-1,4-dièn-3-ones et de cyclohexanones substitués, dérivés présentant des propriétés antitumorales et antiparasitiques, et composés et leurs utilisations | |
MX2022011601A (es) | Compuestos de oxoisoindolina sustituidos para el tratamiento del cancer. | |
MA40934A (fr) | Procédé de préparation de conjugués agent de liaison cellulaire-agent cytotoxique | |
MX2020012309A (es) | Moleculas de union a gp41 optimizadas y usos de las mismas. | |
WO2017136623A8 (fr) | Procédé efficace de préparation de conjugués agent de liaison cellulaire-agent cytotoxique |